CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30⁺ and CD30^- Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions.

ABSTRACT: Tumor antigen heterogeneity limits success of chimeric antigen receptor (CAR) T-cell therapies. Embryonal carcinomas (EC) and mixed testicular germ cell tumors (TGCT) containing EC, which are the most aggressive TGCT subtypes, are useful for dissecting this issue as ECs express the CD30 antigen but also contain CD30^-/dim cells. We found that CD30-redirected CAR T cells (CD30.CAR T cells) exhibit antitumor activity in vitro against the human EC cell lines Tera-1, Tera-2, and NCCIT and putative EC stem cells identified by Hoechst dye staining. Cytolytic activity of CD30.CAR T cells was complemented by their sustained proliferation and proinflammatory cytokine production. CD30.CAR T cells also demonstrated antitumor activity in an in vivo xenograft NOD/SCID/γcnull (NS

SUBMITTER: Hong LK 

PROVIDER: S-EPMC7590161 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature